--- title: "Hong Kong's Island of Misfit Stocks: Who Is Actually Making Money?" type: "News" locale: "en" url: "https://longbridge.com/en/news/293118650.md" description: "Throwing AI healthcare, state banks, and rail behemoths into one bucket is absurd. Yet this odd lot reflects reality: Yidu Tech finally profits, Yixin expands overseas, while legacy giants hide behind dividends." datetime: "2026-07-19T09:12:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293118650.md) - [en](https://longbridge.com/en/news/293118650.md) - [zh-HK](https://longbridge.com/zh-HK/news/293118650.md) generator: "portal-rs" --- # Hong Kong's Island of Misfit Stocks: Who Is Actually Making Money? Throwing an AI healthcare startup, a state-owned bank, a Tencent-backed auto financier, and a rail behemoth into the exact same bucket is stupid, and here's why. It feels like an island of misfit stocks, an arbitrary grab bag of Hong Kong's unclassifiables. Yet, if you look closely at this "Other" category, it perfectly encapsulates the schizophrenic reality of the 2026 market: some are finally waking up and printing cash, while legacy giants are fast asleep at the wheel. Take Yidu Tech (2158.HK). For years, AI healthcare was just a buzzword to burn venture capital. Now, they are actually delivering. They posted their first full-year profit in FY2026 (ended March 2026), pulling in 78.77 million RMB in net income. They even had a Saudi delegation knocking on their door in July. The stock has clawed back some ground recently. But why aren't they moving faster? The AI window won't stay open forever. Yixin Group (2858.HK) is the only other one here that genuinely catches my eye. While domestic EV makers are slashing throats in a bloody price war, Tencent's auto finance arm is quietly making a killing abroad. Their overseas financing volume surged roughly 3x in Q1 2026, and their fintech SaaS revenue skyrocketed 150% in 2025. Going global while everyone else brawls at home? Smart move. Then we have the sleeping giants. CRRC (1766.HK) casually scooped up 51.64 billion RMB in major contracts in Q2 2026. The state-backed infrastructure gravy train is real, and the stock has rightfully outperformed the broader market. Contrast that with Postal Savings Bank of China (1658.HK). They missed estimates on both Q1 2026 revenue (78.47 billion RMB) and EPS (0.20 RMB), yet investors still huddle there because it's supposedly a "resilient, high-dividend" play. Hiding behind dividends to mask sluggish growth? Good luck with that. The rest are either tragic or boring. SPT Energy Group (2178.HK) finally swung to a 22.9 million HKD profit in 2025 thanks to higher oil prices, only to get slapped with a 16.8 million RMB lawsuit payout in May 2026. That profit evaporated as quickly as it arrived. Meanwhile, Tradelink (0536.HK) squeezed out a 2.5% profit growth in 2025 off its government e-trade monopoly. It is about as thrilling as watching paint dry. To round out this odd collection, you have China Mobile-R (80941.HK) for those who want a telecom utility while dodging currency risks, and the iShares MSCI Asia ex-Japan ETF (3010.HK) for when you want exposure but are too lazy to pick stocks. Oh, and Zhenjiankang Medical-B (2697.HK)? In this ruthless 2026 market, biotech B-shares need more than just a ticker to survive. My view is clear: stop paying for arbitrary themes and start looking at who is actually printing money in a fractured market. *This article does not constitute investment advice.* ### Related Stocks - [02158.HK](https://longbridge.com/en/quote/02158.HK.md) - [02858.HK](https://longbridge.com/en/quote/02858.HK.md) - [01766.HK](https://longbridge.com/en/quote/01766.HK.md) - [01658.HK](https://longbridge.com/en/quote/01658.HK.md) - [02178.HK](https://longbridge.com/en/quote/02178.HK.md) - [80941.HK](https://longbridge.com/en/quote/80941.HK.md) - [02697.HK](https://longbridge.com/en/quote/02697.HK.md) ## Related News & Research - [PSBC 1H26 Net Profit Up 4.6% to RMB51.5B; Interim DPS Hikes 8.1% to RMB0.133](https://longbridge.com/en/news/297298563.md) - [CRRC Schedules Online Briefing to Discuss 2026 Interim Results with Investors](https://longbridge.com/en/news/297647257.md) - [CRRC schedules interim results briefing](https://longbridge.com/en/news/297641477.md) - [Yixin FY26 H1 net profit rises 28.2% to RMB 703.6 million; revenue increases 13.3% to RMB 6.2 billion](https://longbridge.com/en/news/297629386.md) - [Guangdong True Health signs sales contract worth up to RMB 100 million](https://longbridge.com/en/news/297484935.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**